Key Takeaways
- Operating leverage delivered a 20x multiplier: A 4.6% revenue increase translated into nearly 20x growth in operational PAT, as gross margins expanded 500 bps YoY to 57.8% and EBITDA conversion surged.
- U.S. growth is steady, not spectacular: Revenue hit $73 million, up 2% YoY, with the company holding a top-three rank in 37 products. The path to $400 million by FY28 will be "very steady" over 2.5 years, with management prioritizing profitability over pace.
- Margin discipline is structural, not cyclical: Gross margins have held a 55–59% range for six quarters, driven by a deliberate philosophy of rejecting loss-leader products and onboarding only revenue that meets strategic margin thresholds or absorbs plant under-recoveries.
- The balance sheet is quietly strengthening: Operational cash conversion hit 87% of EBITDA, enabling INR73 crores of debt reduction despite a INR71 crore forex headwind; the net debt-to-EBITDA ratio improved from 1.9x to 1.65x.
- What to watch next quarter: Whether the calibrated U.S. launch cadence accelerates to close the gap toward the 60-product target, the trajectory of gross margins as competitive intensity rises, and any firming of the "beyond FY28" growth-market pipeline.
The Operating Leverage Story
- Multiplier effect in action: A modest 4.6% top-line increase generated 3x that rate in gross margin growth, 5–6x in EBITDA growth, and roughly 20x in operational PAT, demonstrating the power of fixed-cost absorption as plants move toward full utilization.
- Under-recovery tailwind remains: Management confirmed there is still slack across plants, meaning incremental revenue can be added without proportionate new operating costs, leaving further leverage to be extracted.
- Gross margin structure: The 500 bps YoY expansion to 57.8% is described as "fairly structural," having held in a 55–59% band for six quarters and expanding in a calibrated manner through disciplined onboarding of new business.
- Cost discipline: Operating costs held steady at 39% of sales, and the company explicitly dropped five or six products across the U.S. and U.K. that did not meet profitability thresholds, reinforcing the philosophy of profit over volume.
Badree Komandur: "All we want to say is that consistency and sustainable growth has helped us to create the operating leverage, and the multiplier effect is very clearly seen from our results, a 4.6% increase in revenue growth resulted in almost 3x increase in gross margin growth, almost 5x to 6x increase in the EBITDA growth, and almost 20x increase in the operational PAT."
U.S. Market: Steady March to $400 Million
- Current state: U.S. revenue of $73 million grew 2% YoY, maintaining the $70 million+ range for five consecutive quarters after stepping up from a $65 million base. The company holds a top-three ranking in 37 products that contribute 75% of U.S. revenue.
- The $400 million target: Management reaffirmed the FY28 goal and characterized the path as "very steady" over the next 2.5 years, with sustainability of that target the primary focus. External events remain a watchpoint.
- Launch philosophy: The company deliberately waits for market disruption before launching, rather than rushing products to market upon approval. This timing strategy, combined with premium service levels, creates customer stickiness but also means the launch cadence is uneven and hard to forecast quarter-by-quarter.
- Portfolio pruning: A few products were dropped from commercialization for failing profitability thresholds, and five or six were discontinued across U.S. and U.K. markets in H1. New R&D spending is directed at Control Substances and programs beyond the $400 million target.
- Competitive intensity: Management acknowledged competition but declined to specify how long elevated intensity typically lasts, instead pointing to AVD programs and cost improvement plans as mitigants. The company "does not want to compromise the profitability of the company at the cost of top line growth."
Badree Komandur: "Yes, it will be very steady. That's all we can say that in the next 2.5 years, we should be able to get there is our hope. But of course, external events are there. We have to watch out, and we want to take step by step. And most important thing is we are focused on the sustainability of that revenue or sustainability of that target."
Other Regulated Markets: The Second Engine
- Growth trajectory: Other regulated markets grew 16% YoY, stepping up from a $40 million to a $44 million range. These markets benefit from high entry barriers due to divergent regulatory pathways, creating a moat.
- Long-term aspiration: Management aims to mirror the U.S. market in size within 2–3 years, implying a run rate approaching $100 million. Deal momentum in Europe is building, with large pan-EU partners being onboarded, while the U.K. has formed a stable new base.
- Portfolio maximization: Growth over the last six quarters has been driven by portfolio build-up and maximization, with all pivots now in place for accelerated expansion.
Badree Komandur: "Yes. That is what is our plan. And it will -- again, that's a long-term aspiration. When it will happen, we don't know, but we are working towards it."
Beyond Generics: Nasal Sprays and Control Substances
- Nasal Spray pipeline: One product has been filed, with a few more expected in the next 12 months. Approval and launch are roughly 18–24 months from the current date, placing revenue contribution in FY28 or later. Management declined to specify therapy areas.
- Control Substances seeding: This is the first full year of execution, with one or two products launched. The business is still being built and is not yet a material revenue contributor.
- R&D spend: The company is on track to spend $15–20 million on R&D, focused on Nasal Sprays and Beyond Generics. Internal R&D flows through the P&L, while bought-out ANDA acquisitions are capitalized.
- ANDA acquisitions: A few ANDAs were acquired for near-to-medium-term growth, contributing to the INR100 crores increase in intangibles, though management declined to quantify the number or opportunity size.
Growth and Access Markets: Mixed Signals
- Growth markets: Revenue of $17 million grew 7% YoY, with Africa performing particularly well in the quarter. Substantial growth is expected beyond FY28, with regulatory filings and go-to-market planning underway, but new dollars are not anticipated until FY27–FY28.
- Access markets: These remain lumpy and challenged by a difficult donor-funding environment. The second half is expected to be slightly better than the first, but outcomes depend on donor agencies' decisions, an external variable outside management's control.
Balance Sheet and Cash Flow
- Cash conversion: Operational cash of INR394 crores represented 87% EBITDA-to-cash conversion, enabling free cash of INR73 crores directed entirely to debt reduction.
- Debt improvement: Net debt fell by INR73 crores despite a INR71 crore adverse forex impact from balance sheet restatement, which is a non-P&L item. The EBITDA-to-net-debt ratio improved from 1.9x to 1.65x.
- Finance costs: Gross finance costs continue to improve quarter-on-quarter. Net finance costs for H1 were significantly lower YoY due to interest income on certain refunds, but H2 net costs may rise slightly as that income does not repeat.
- Capex: H1 capex of INR149 crores covered maintenance and growth investments including intangibles; similar levels are expected in H2.
- Tax rate: The effective tax rate is expected to remain in the 15–20% range for the full year.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| U.S. revenue target | Reach $400 million run rate | By FY28 |
| Other regulated markets aspiration | Mirror U.S. market size (~$100 million run rate) | Next 2–3 years |
| Gross margin range | Sustain 55–59% band through disciplined onboarding | Ongoing, held for 6 quarters |
| R&D spend | $15–20 million annually | FY26 |
| Nasal Spray filings | File a few more products | Next 12 months |
| Nasal Spray revenue contribution | Approval and launch of filed products | 18–24 months from now |
| Growth markets step-up | Substantial new dollars from regulatory and GTM efforts | Beyond FY27–FY28 |
| Capex | Maintain H1 run rate (~INR149 crores per half) | H2 FY26 |
| Effective tax rate | 15–20% | Full year FY26 |
| Debt reduction | Apply free cash to reduce debt | Ongoing |
| Finance costs | Gross finance costs to continue improving; net costs may rise slightly in H2 | H2 FY26 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue growth | 4.6% YoY |
| Gross margin | 57.8%, INR706 cr, up 500 bps YoY |
| EBITDA | INR232 cr, margin 19%, up 320 bps YoY |
| Operational PAT | INR140 cr, highest ever quarterly operational PAT |
| Operational EPS | INR15.2, highest ever quarterly EPS |
| Reported PAT | INR132 cr |
| EBITDA to operational PAT conversion | 57% |
| Operating costs | 39% of sales |
| U.S. revenue | $73 million, +2% YoY |
| Other regulated markets growth | 16% YoY |
| Growth markets revenue | $17 million, +7% YoY |
| Rest of world markets revenue | INR1,030 cr, crossed INR1,000 cr threshold |
| Net debt | INR1,449 cr, EBITDA to net debt ratio at 1.65x |
| ROCE | 16%, improved from 14.9% in March '25 |
| Cash-to-cash cycle | 113 days, improved 3 days QoQ |